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Previewsacquire resistance to cisplatin and PARP
inhibitors. Aside from allowing clinicians
to anticipate such a response, if a patient
should carry a tumor with this class of
mutation, what could be the possible
mechanism that gives rise to this? We
do not know; however it does seem that
these tumors tolerate the accumulation
of DNA damage or that they are able to
switch on compensatory repair pathways
that require a BRCA1 function that is not
affected by this mutation, or a combina-
tion of both. All in all, these studies
provide new murine models for mutant
BRCA1-driven breast carcinogensis,
providing intriguing new results and an
excellent platform for future studies.REFERENCES
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In this issue of Cancer Cell, Snuderl and coworkers demonstrate intratumoral genetic heterogeneity in glio-
blastoma based on in situ amplification of distinct genomic loci within individual cells in a mutually exclusive
pattern. These findings may herald trouble for current targeted therapies but provide insights for future treat-
ment strategies.Glioblastoma multiforme (GBM) is among
the most lethal of all human cancers with
a median survival of about 14 months
despite aggressive surgical resection
and adjuvant chemotherapy with radia-
tion (Stupp et al., 2005). Nevertheless,
the clinical course of some GBM patients
can be highly variable, which may, in part,
be attributable to the recent identification
of a least four molecular subtypes of GBM
(Verhaak et al., 2010). These molecular
subtypes, however, do not explain the
diverse array of pathological findings
within any given GBM including morpho-
logically distinct tumor cells with various
patterns of growth (e.g., bulky tumor to
single cell invasion along white mater
tracks) and variable effects on the host
tissue that are pathognomonic of thedisease and responsible for the designa-
tion ‘‘multiforme’’ (Bailey and Cushing,
1926).
One potential explanation for the diver-
sity of intratumoral findings is that the
phenotype of the GBM clonogenic or
stem cell is plastic and variable, affected
by both intracellular (e.g., stochastic) and
extracellular (e.g., microenvironmental)
stimuli. Asa result, the variablephenotypes
may represent different degrees of aber-
rant differentiation of a cancer stem cell.
A more complex and therapeutically chal-
lenging explanation for the clinical and
pathologic variability of GBMs, however,
is that we are actually dealing with
‘‘different tumors’’ within a given patient.
The term ‘‘tumor heterogeneity’’ can be
defined as the presence of subclones ofcells, within a given tumor, with different
genetic aberrations that mediate diver-
gent biology that define the natural history
of that particular tumor (Navin et al., 2011;
Yachida et al., 2010). Although not a
new idea, the recent advent of high-
throughput molecular and genetic meth-
odologies has begun to explore the nature
of this phenomenon. To that end, several
recent papers have used high-resolution
chromosomal copy number analysis and
next generation sequencing to show
a range of genetically divergent tumor
cell clones within leukemia (Stephens
et al., 2011), breast cancer (Navin et al.,
2011), and pancreatic cancer (Yachida
et al., 2010).
In this issue ofCancer Cell, Snuderl and
co-workers (2011) use fluorescenceecember 13, 2011 ª2011 Elsevier Inc. 695
Figure 1. Intratumoral Clonal Heterogeneity
Three possible but nonmutually exclusive scenarios for interaction between subclones within tumors.
(A) ‘‘Founder’’ cell undergoes ‘‘progressor’’ mutations that generate three subclones: blue, yellow, and green.
(B) Random distribution of subclones within tumor body showing no association with specific niche or function. Niche-based distribution of subclones within the
tumor body: hypoxic region (blue), oxygen rich regions (green), and invasive front (yellow). Organ system paradigm or function-based distribution of subclones
within tumor body. Autocrine and paracrine TGF-b secretion (green), VEGF secretion (yellow), and endothelial cell trans-differentiation (blue). *Scenario-specific
therapeutic targets.
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Previewsin situ hybridization (FISH) to ‘‘genotype’’
individual tumor cells within a given
GBM by probing for three of the most
commonly amplified loci that encode
receptor tyrosine kinase (RTK) in GBM
(EGFR, PDGFRA and c-MET). Their
results show that individual RTK and
combinations of RTKs are amplified in
different cells within a given tumor in a
mutually exclusive pattern. Furthermore,
they find evidence that many of the cells
within these subclones express phospho-
histone H3, indicating a proliferative state.
Finally, they present evidence suggesting
that the subclones are descendants of
a common precursor based on the pre-
sence of CDKN2A deletion and/or a
common TP53 mutation.
The demonstration of these genomic
subclones in GBM raises a plethora of
new questions such as the number of
subclones within a given tumor, the696 Cancer Cell 20, December 13, 2011 ª20genomic relatedness of one clone to
another (i.e., the ‘‘evolutionary tree’’ of
the clones), and the mechanistic basis
for the genomic heterogeneity. Answers
to these questions may be tumor specific
and will require methodologies with much
higher genomic resolution than those
used by Snuderl and co-workers such as
next-generation sequencing (Navin et al.,
2011).
One of the most important questions
regarding these subclones is their indi-
vidual and/or combined functional role
during the pathogenesis of the tumor.
One possibility is that each subclone is
randomly generated and selected for
through competitionwith some subclones
and/or passive coexistence with others
rather than direct interaction between
subclones. A second possibility is that
each subclone is selected for by its
genetic and epigenetic predisposition to11 Elsevier Inc.optimally occupy a specific niche within
the variable microenvironment of the
tumor. For instance, one subclone may
thrive in the relatively oxygen rich environ-
ment of a highly angiogenic portion of the
tumor, whereas another subclone may be
preferentially suited for hypoxic regions
(Figure 1). Likewise, other subclones may
be enriched with signaling pathways
allowing efficient invasion and migration
into normal surrounding cerebral cortex
coopting pre existing cerebral vasculature
along the way (Figure 1). Finally, a third
but not mutually exclusive possibility,
envisions the GBM as an ‘‘organ system’’
and each subclone serves as a ‘‘tissue
type’’ with a unique function within the
life cycle of the tumor organ system. For
instance, recent evidence suggests that
some GBM stem cells can trans-differen-
tiate into endothelial cells and contribute
to tumor vasculogenesis (Ricci-Vitiani
Cancer Cell
Previewset al., 2010). Other subclones may prefer-
entially secrete angiogenic factors to
support these new blood vessels
(Figure 1). Also, some GBM subclones
may express specific mitogenic receptors
such as Notch (Wang et al., 2010),
whereas others may express their ligands
in a paracrine manner (Figure 1). Finally,
subclones may also support the entire
tumor through the expression of cyto-
kines such as TGF-b that not only
enhance GBM stem cell self-renewal but
may provide an immunosuppressive
microenvironment that protects the tumor
from host immune surveillance and attack
(Wu et al., 2010) (Figure 1).
The reality of both intertumoral and
intratumoral heterogeneity have major
therapeutic implications. The recent eluci-
dation of four different gene expression-
based GBM subtypes (e.g., intertumoral
heterogeneity) (Verhaak et al., 2010) gives
hope for being able to ultimately identify
‘‘targeted treatment’’ for molecular
targets and pathways specific for those
subtypes and to enrich for patient popula-
tions likely to benefit from any new
targeted therapy in future clinical trials.
By contrast, the concept of intratumoral
genomic heterogeneity poses a daunting
therapeutic prospect and successful
strategies to target multiple subclones
will depend on how those subclones
interact within a tumor. For example, if
the subclones are functionally dependent
on each other within the context of the
tumor ‘‘organ system’’ paradigm dis-
cussed above, then it may be possible
to target one or two of the most critical
subclones with the hope that their extinc-
tion will lead to the collapse of the tumor
as a whole (Figure 1). Alternately, if the
subclones exist and thrive in particularmicroenvironmental niches, then it may
be possible to use a combination of
agents that target those environments
such as antiangiogenic agents, hypoxic
drug sensitizers, and anti-invasion mole-
cules (Figure 1).
Most problematic, however, is the
scenario where subclones exist largely
independent of each other making their
elimination profoundly more difficult. In
such a case, the hope would be to identify
‘‘founder mutations’’ (Yachida et al., 2010)
that were present in the initial clonogenic
tumor population and inherited by subse-
quent divergent subclones. Indeed, Snu-
derl and co-workers found evidence that
deletion of CDKN2A and TP53 mutations
may be such founder mutations in the
GBMs studied (Snuderl et al., 2011).
Even if such founder mutations are found
in all subclones, however, successful
therapeutic targeting of these mutations
requires that the divergent subclones
retain dependence on these aberrant
pathways and that the subsequent ‘‘pro-
gressor mutations’’ that define these
divergent subclones do not instill func-
tional independence from the initial
founder mutations. If the latter were true,
therapeutic success here would entail
targeting each individual subclone,
something that would be theoretically
possible only if a few tumorigenic sub-
clones exist. If, however, numerous
mechanistically independent tumorigenic
subclones coexist within a tumor, the
prospect of identifying, selecting, and
administrating multiple targeted therapies
simultaneously to any given patient
becomes much more challenging. In
such a situation, it may be necessary to
resort to our old paradigm of developing
cytotoxic rather than targeted therapies.Cancer Cell 20, DFor our patients’ sake, we can only hope
this does not turn out to be the case given
the disappointing record with such agents
in the past (Stupp et al., 2005).REFERENCES
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